000			02098 a2200613 4500
005			20250516015139.0
264		0	_c20111202
008			201112s 0 0 chi d
022			_a0253-3766
040			_aNLM _beng _cNLM
100	1		_aLin, Li
245	0	0	_a[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer]. _h[electronic resource]
260			_bZhonghua zhong liu za zhi [Chinese journal of oncology] _cOct 2010
300			_a786-90 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article
650	0	4	_aAdenocarcinoma _xblood
650	0	4	_aAdenocarcinoma, Mucinous _xblood
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAngiogenesis Inhibitors _xadverse effects
650	0	4	_aAntibodies, Monoclonal, Humanized _xadverse effects
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBevacizumab
650	0	4	_aCA-19-9 Antigen _xblood
650	0	4	_aCamptothecin _xadministration & dosage
650	0	4	_aCarcinoembryonic Antigen _xblood
650	0	4	_aColonic Neoplasms _xblood
650	0	4	_aDiarrhea _xchemically induced
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aFluorouracil _xadministration & dosage
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aHypertension _xchemically induced
650	0	4	_aIrinotecan
650	0	4	_aLeucovorin _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeutropenia _xchemically induced
650	0	4	_aRectal Neoplasms _xblood
650	0	4	_aRemission Induction
650	0	4	_aRetrospective Studies
650	0	4	_aSurvival Rate
650	0	4	_aYoung Adult
700	1		_aXu, Jian-ming
700	1		_aWang, Yan
700	1		_aGe, Fei-jiao
700	1		_aLiu, Lie-jun
700	1		_aZhao, Chuan-hua
700	1		_aLi, Shan-shan
700	1		_aLiu, Jian-zhi
700	1		_aLi, Zhi-qiang
773	0		_tZhonghua zhong liu za zhi [Chinese journal of oncology] _gvol. 32 _gno. 10 _gp. 786-90
999			_c20451969 _d20451969